Explore more publications!
Asia Healthcare Industry Digest
Got News to Share?

Press Releases

HOTEL de DOCTOR 24 Releases Free Guide for Australian Travelers: 'How to Handle Illness and Medication in Japan' - DELETED
14 hours ago

HOTEL de DOCTOR 24 Releases Free Guide for Australian Travelers: 'How to Handle Illness and Medication in Japan' - DELETED

Neutral EIN Presswire
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Ardent Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDT
Feb. 1, 2026

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Ardent Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDT

Indeterminate GlobeNewswire, Inc.
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages agilon health, inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AGL
Feb. 1, 2026

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages agilon health, inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AGL

Indeterminate GlobeNewswire, Inc.
The 2026 Powerhouse: Why Shandong Hesper Ranks Among China's Top 10 Industrial Hose Manufacturers
Feb. 1, 2026

The 2026 Powerhouse: Why Shandong Hesper Ranks Among China's Top 10 Industrial Hose Manufacturers

Neutral EIN Presswire
Japan Records 532 Child Suicides in 2025
Jan. 29, 2026

Japan Records 532 Child Suicides in 2025

Indeterminate MENAFN
Owner: Sawsan Dababneh & Ramzi AbdelJaber

MENAFN

Indeterminate
Owned By Sawsan Dababneh & Ramzi AbdelJaber through The Middle East North Africa Financial Network, Inc
Year Founded 2000
Website menafn.com
Domain Registration Year Indeterminate
Access Type open
Publication Location Amman, New York, Dubai

We welcome your feedback!
If you have comments or corrections, let us know.

Chinese Neurosurgical Journal Highlights Eosinophils as a Potential Target in Chordoma Treatment
Jan. 30, 2026

Chinese Neurosurgical Journal Highlights Eosinophils as a Potential Target in Chordoma Treatment

Neutral EIN Presswire
China SXT Pharmaceuticals, Inc. Announces Share Consolidation
Jan. 30, 2026

China SXT Pharmaceuticals, Inc. Announces Share Consolidation

Indeterminate GlobeNewswire, Inc.
Japan and Uttar Pradesh, India Explore Expanded Cooperation in Wellness, Cultural and Experiential Tourism
Jan. 30, 2026

Japan and Uttar Pradesh, India Explore Expanded Cooperation in Wellness, Cultural and Experiential Tourism

Neutral EIN Presswire
Pacific Financial Corp Reports Fourth Quarter 2025 Earnings of $3.1 Million, or $0.31 per Diluted Share; Declares Quarterly Cash Dividend of $0.15 per Share
Jan. 30, 2026

Pacific Financial Corp Reports Fourth Quarter 2025 Earnings of $3.1 Million, or $0.31 per Diluted Share; Declares Quarterly Cash Dividend of $0.15 per Share

Indeterminate GlobeNewswire, Inc.
Chinese Top 3 Passenger Elevator Manufacturers 2026 - Leading the Global Elevator Market
Jan. 30, 2026

Chinese Top 3 Passenger Elevator Manufacturers 2026 - Leading the Global Elevator Market

Neutral EIN Presswire
Chinese Top 3 Alfa Laval Plate Heat Exchanger Manufacturers 2026-Driving Innovation in Global Thermal Exchange Solutions
Jan. 30, 2026

Chinese Top 3 Alfa Laval Plate Heat Exchanger Manufacturers 2026-Driving Innovation in Global Thermal Exchange Solutions

Neutral EIN Presswire
Oxford Healthspan to Introduce New Primeadine® GF Powder Through a ‘Longevity Shot’ Experience During Grammy Week in Los Angeles
Jan. 30, 2026

Oxford Healthspan to Introduce New Primeadine® GF Powder Through a ‘Longevity Shot’ Experience During Grammy Week in Los Angeles

Indeterminate GlobeNewswire, Inc.
RegulatingAI Podcast with Sanjay Puri: How Abhishek Singh Is Building India’s Vision for Responsible AI at Scale
Jan. 30, 2026

RegulatingAI Podcast with Sanjay Puri: How Abhishek Singh Is Building India’s Vision for Responsible AI at Scale

Neutral EIN Presswire
Healthcare Mobility Solutions Market Accelerates at 20.44% CAGR, Targeting USD 1.05 Trillion by 2034
Jan. 29, 2026

Healthcare Mobility Solutions Market Accelerates at 20.44% CAGR, Targeting USD 1.05 Trillion by 2034

Indeterminate GlobeNewswire, Inc.
Arctic Vision Announces Deal to Integrate MDCO Technology’s Ophthalmic Device Business to Form a Global Drug–Device Innovation Platform
2 hours ago

Arctic Vision Announces Deal to Integrate MDCO Technology’s Ophthalmic Device Business to Form a Global Drug–Device Innovation Platform

Indeterminate GlobeNewswire, Inc.
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU
Jan. 30, 2026

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU

Indeterminate GlobeNewswire, Inc.
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of 2mg/kg Body Weight Every-Four-Weeks for Elfabrio® (pegunigalsidase alfa) ▼ in the EU
Jan. 30, 2026

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of 2mg/kg Body Weight Every-Four-Weeks for Elfabrio® (pegunigalsidase alfa) ▼ in the EU

Indeterminate GlobeNewswire, Inc.
Holistic Health Practitioner Xiomara Hoey of Xiomara Empowered Health Recently Featured on Close Up Radio
Jan. 30, 2026

Holistic Health Practitioner Xiomara Hoey of Xiomara Empowered Health Recently Featured on Close Up Radio

Neutral EIN Presswire
Press Release: Sanofi’s Rezurock recommended for EU approval by the CHMP to treat chronic graft-vs-host disease
Jan. 30, 2026

Press Release: Sanofi’s Rezurock recommended for EU approval by the CHMP to treat chronic graft-vs-host disease

Indeterminate GlobeNewswire, Inc.
Kyowa Kirin to Regain Control of Rocatinlimab Development and Commercialization Program, Demonstrating Strong Commitment to Address High Unmet Medical Need in Atopic Dermatitis
Jan. 30, 2026

Kyowa Kirin to Regain Control of Rocatinlimab Development and Commercialization Program, Demonstrating Strong Commitment to Address High Unmet Medical Need in Atopic Dermatitis

Indeterminate GlobeNewswire, Inc.
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions